References

Parkinson’s disease

10.1016/s0140-6736(14)61393-3 · 2015 · External reference

“Pure apathy” and cognitive dysfunctions in Parkinson’s disease: a meta-analytic study

10.1016/j.neubiorev.2018.08.004 · 2018 · External reference

Neurobiologic rationale for treatment of apathy in Alzheimer’s disease with methylphenidate

10.1016/j.jagp.2020.04.026 · 2021 · External reference

Efficacy of methylphenidate in patients with brain disease: a systematic review and meta-analysis

10.12786/bn.2025.18.e4 · 2025 · External reference

Methylphenidate for apathy in community dwelling older veterans with mild Alzheimer’s disease: a double-blind, randomized, placebo-controlled trial

10.1176/appi.ajp.2017.17030316 · 2018 · External reference

Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function

10.1016/j.biopsych.2006.04.022 · 2006 · External reference

10.2174/187152708786927877

10.2174/187152708786927877 · External reference

Monoamine transporter inhibitors and substrates as treatments for stimulant abuse

10.1016/b978-0-12-420118-7.00004-4 · 2014 · External reference

(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) — a novel cortical-preferring catecholamine transmission- and cognition-promoting agent

10.1124/jpet.120.000037 · 2020 · External reference

First-in-human study to assess the safety, tolerability, and pharmacokinetics of Pirepemat, a cortical enhancer, in healthy volunteers

10.1002/cpdd.959 · 2021 · External reference

A phase 2a trial investigating the safety and tolerability of the novel cortical enhancer IRL752 in Parkinson’s disease dementia

10.1002/mds.28020 · 2020 · External reference

Involvement of cortical dysfunction in frequent falls in patients with Parkinson’s disease

10.1016/j.parkreldis.2019.04.007 · 2019 · External reference

Influence of serotonin 5-HT7 receptor blockade on the behavioral and neurochemical effects of imipramine in rats

2008 · External reference

Pharmacology and therapeutic potential of the 5-HT7 receptor

10.1021/acschemneuro.8b00283 · 2019 · External reference

Differential α2A- and α2C-adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex

10.1177/0269881118798612 · 2019 · External reference

Therapeutic potential of selectively targeting the α2C-adrenoceptor in cognition, depression, and schizophrenia-new developments and future perspective

10.3389/fpsyt.2017.00144 · 2017 · External reference

In vivo systems response profiling and multivariate classification of CNS active compounds: a structured tool for CNS drug discovery

10.1021/acschemneuro.6b00371 · 2017 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

D-amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats

10.1016/s0149-7634(98)00020-7 · 1998 · External reference

Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review

10.3389/fpsyt.2024.1508732 · 2024 · External reference

Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs

10.1186/1471-2210-6-6 · 2006 · External reference

Targeting the serotonin 5-HT7 receptor in the search for treatments for CNS disorders: rationale and Progress to date

10.1007/s40263-015-0236-0 · 2015 · External reference

Current limitations and candidate potential of 5-HT7 receptor antagonism in psychiatric pharmacotherapy

10.3389/fpsyt.2021.623684 · 2021 · External reference

Design and discovery of a high affinity, selective and β-Arrestin biased 5-HT7 receptor agonist

10.1007/s00044-021-02797-4 · 2022 · External reference

Unresolved reference

External reference